Mosley Wealth Management
VRTX icon

Mosley Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mosley Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.58K Hold
9
– – ﹤0.01% 438
2026
Q2 		$4.47K Buy
+9
New +$3.99K ﹤0.01% 441

Other funds holding VRTX

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $59.1B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mosley Wealth Management's VRTX Position: Q3 2026 in Review

Mosley Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 9 shares worth $4.58K. The position accounts for ﹤0.01% of the portfolio, ranked #438.

Mosley Wealth Management first reported a position in VRTX in Q2 2026 and has held it in 2 quarters since. 1,193 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Mosley Wealth Management held 9 shares of Vertex Pharmaceuticals worth $4.58K as of Q3 2026.
  • Mosley Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Mosley Wealth Management's portfolio in Q3 2026, its #438 holding.
  • Mosley Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 1,193 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Mosley Wealth Management's 13F filing for Q3 2026, filed 16 Oct 2026.